Amphastar Pharmaceuticals, Inc. announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
